SG11202108909SA - Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate - Google Patents
Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrateInfo
- Publication number
- SG11202108909SA SG11202108909SA SG11202108909SA SG11202108909SA SG11202108909SA SG 11202108909S A SG11202108909S A SG 11202108909SA SG 11202108909S A SG11202108909S A SG 11202108909SA SG 11202108909S A SG11202108909S A SG 11202108909SA SG 11202108909S A SG11202108909S A SG 11202108909SA
- Authority
- SG
- Singapore
- Prior art keywords
- trifluoromethyl
- dihydroisoquinolin
- pyrazole
- pyridin
- oxo
- Prior art date
Links
- HVWKJSJNIWVJGF-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide hydrate Chemical compound C1=CC2=C(C=CNC2=O)C(=C1)N3C(=C(C=N3)C(=O)NC4=CC(=NC=C4)C(F)(F)F)C(F)(F)F.O HVWKJSJNIWVJGF-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019075834 | 2019-02-22 | ||
| PCT/EP2020/054485 WO2020169736A1 (en) | 2019-02-22 | 2020-02-20 | Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108909SA true SG11202108909SA (en) | 2021-09-29 |
Family
ID=69723907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108909SA SG11202108909SA (en) | 2019-02-22 | 2020-02-20 | Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US12269813B2 (enExample) |
| EP (1) | EP3927696B1 (enExample) |
| JP (1) | JP2022523368A (enExample) |
| KR (1) | KR20210131371A (enExample) |
| CN (1) | CN113474339B (enExample) |
| AU (1) | AU2020226723B2 (enExample) |
| BR (1) | BR112021016400A2 (enExample) |
| CA (1) | CA3129623A1 (enExample) |
| EA (1) | EA202192320A1 (enExample) |
| EC (1) | ECSP21067828A (enExample) |
| ES (1) | ES2966132T3 (enExample) |
| IL (1) | IL285675A (enExample) |
| JO (1) | JOP20210227A1 (enExample) |
| MA (1) | MA55019A (enExample) |
| MX (1) | MX2021010133A (enExample) |
| PE (1) | PE20212067A1 (enExample) |
| PH (1) | PH12021552018A1 (enExample) |
| SG (1) | SG11202108909SA (enExample) |
| TW (1) | TW202045495A (enExample) |
| UY (1) | UY38592A (enExample) |
| WO (1) | WO2020169736A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| US12404260B2 (en) | 2019-04-11 | 2025-09-02 | Janssen Pharmaceutica Nv | Pyridine rings containing derivatives as MALT1 inhibitors |
| BR112023003106A2 (pt) | 2020-08-21 | 2023-04-04 | Janssen Pharmaceutica Nv | Forma amorfa de um inibidor de malt1 e formulações do mesmo |
| BR112023017689A2 (pt) | 2021-03-03 | 2023-11-14 | Janssen Pharmaceutica Nv | Método de tratamento de uma condição com o uso de uma dose terapeuticamente eficaz do inibidor de malt1 jnj-67856633 (1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil)-n(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida) |
| EP4301365A1 (en) | 2021-03-03 | 2024-01-10 | Janssen Pharmaceutica NV | Combination therapy using a malt1 inhibitor and a btk inhibitor |
| AU2022326183A1 (en) * | 2021-08-09 | 2024-03-28 | Janssen Pharmaceutica Nv | Compositions for use in treating b-cell malignancies |
| WO2025073968A1 (en) | 2023-10-06 | 2025-04-10 | Ionctura Sa | Combination of roginolisib with a malt1-gls inhibitor |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007525183A (ja) | 2003-04-30 | 2007-09-06 | アジェンシス， インコーポレイテッド | 癌の処置および検出において有用な１０９ｐ１ｄ４と称される、核酸および対応タンパク質 |
| WO2007111904A2 (en) * | 2006-03-22 | 2007-10-04 | Vertex Pharmaceuticals Incorporated | C-met protein kinase inhibitors for the treatment of proliferative disorders |
| WO2008092292A1 (en) | 2007-01-17 | 2008-08-07 | The Hong Kong University Of Science And Technology | Isoquinolone compounds as subtype-selective agonists for melatonin receptors mt1 and mt2 |
| WO2011036885A1 (ja) * | 2009-09-25 | 2011-03-31 | 武田薬品工業株式会社 | 複素環化合物 |
| US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| KR101580714B1 (ko) | 2010-06-03 | 2016-01-04 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도 |
| CN102947270B (zh) | 2010-06-22 | 2015-04-08 | 巴斯夫欧洲公司 | 制备4-羟基吡啶的方法 |
| MX2014014531A (es) * | 2012-05-31 | 2015-04-08 | Hoffmann La Roche | Derivados de aminoquinazolina y piridopirimidina. |
| HUE044351T2 (hu) | 2014-05-28 | 2019-10-28 | Novartis Ag | Új pirazolo-pirimidin származékok és azok alkalmazása MALT1 inhibitorként |
| EP3177366A4 (en) | 2014-08-08 | 2018-04-04 | Pharmacyclics LLC | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
| US10835524B2 (en) * | 2015-06-24 | 2020-11-17 | University Of Florida Research Foundation, Incorporated | Compositions for the treatment of pancreatic cancer and uses thereof |
| CA3003820A1 (en) | 2015-11-13 | 2017-05-18 | Novartis Ag | Novel pyrazolo pyrimidine derivatives |
| EP3423452B1 (en) | 2016-03-01 | 2025-05-07 | University of Maryland, Baltimore | Wnt signaling pathway inhibitors for treatments of disease |
| TWI795381B (zh) * | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| EP3576744A1 (en) | 2017-02-01 | 2019-12-11 | Medivir Aktiebolag | Therapeutic applications of malt1 inhibitors |
| US11571427B2 (en) | 2017-12-28 | 2023-02-07 | The General Hospital Corporation | Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment |
| WO2019161921A1 (de) | 2018-02-23 | 2019-08-29 | Industrieanlagen-Betriebsgesellschaft Mbh | Vorrichtung zum erzeugen eines magnetfelds, insbesondere für ein induktives ladesystem, und primäreinrichtung eines induktiven ladesystems zum dynamischen aufladen von fahrzeugen |
| WO2021138298A1 (en) | 2019-12-30 | 2021-07-08 | Rheos Medicines, Inc. | Malt1 modulators and uses thereof |
| BR112023003106A2 (pt) * | 2020-08-21 | 2023-04-04 | Janssen Pharmaceutica Nv | Forma amorfa de um inibidor de malt1 e formulações do mesmo |
-
2020
- 2020-02-20 AU AU2020226723A patent/AU2020226723B2/en not_active Expired - Fee Related
- 2020-02-20 SG SG11202108909SA patent/SG11202108909SA/en unknown
- 2020-02-20 JO JOP/2021/0227A patent/JOP20210227A1/ar unknown
- 2020-02-20 EP EP20707585.4A patent/EP3927696B1/en active Active
- 2020-02-20 EA EA202192320A patent/EA202192320A1/ru unknown
- 2020-02-20 KR KR1020217029765A patent/KR20210131371A/ko not_active Withdrawn
- 2020-02-20 WO PCT/EP2020/054485 patent/WO2020169736A1/en not_active Ceased
- 2020-02-20 MA MA055019A patent/MA55019A/fr unknown
- 2020-02-20 PH PH1/2021/552018A patent/PH12021552018A1/en unknown
- 2020-02-20 CN CN202080015968.5A patent/CN113474339B/zh active Active
- 2020-02-20 US US17/431,447 patent/US12269813B2/en active Active
- 2020-02-20 PE PE2021001372A patent/PE20212067A1/es unknown
- 2020-02-20 CA CA3129623A patent/CA3129623A1/en active Pending
- 2020-02-20 ES ES20707585T patent/ES2966132T3/es active Active
- 2020-02-20 JP JP2021549407A patent/JP2022523368A/ja active Pending
- 2020-02-20 MX MX2021010133A patent/MX2021010133A/es unknown
- 2020-02-20 BR BR112021016400-6A patent/BR112021016400A2/pt not_active Application Discontinuation
- 2020-02-21 UY UY0001038592A patent/UY38592A/es unknown
- 2020-02-21 TW TW109105620A patent/TW202045495A/zh unknown
-
2021
- 2021-08-17 IL IL285675A patent/IL285675A/en unknown
- 2021-09-14 EC ECSENADI202167828A patent/ECSP21067828A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113474339A (zh) | 2021-10-01 |
| US20220127249A1 (en) | 2022-04-28 |
| CA3129623A1 (en) | 2020-08-27 |
| EP3927696A1 (en) | 2021-12-29 |
| PH12021552018A1 (en) | 2022-09-19 |
| JOP20210227A1 (ar) | 2023-01-30 |
| IL285675A (en) | 2021-10-31 |
| WO2020169736A1 (en) | 2020-08-27 |
| TW202045495A (zh) | 2020-12-16 |
| ECSP21067828A (es) | 2021-11-18 |
| AU2020226723B2 (en) | 2025-01-23 |
| UY38592A (es) | 2020-08-31 |
| JP2022523368A (ja) | 2022-04-22 |
| CN113474339B (zh) | 2025-02-25 |
| AU2020226723A1 (en) | 2021-08-19 |
| PE20212067A1 (es) | 2021-10-26 |
| ES2966132T3 (es) | 2024-04-18 |
| MX2021010133A (es) | 2021-09-23 |
| EP3927696B1 (en) | 2023-10-18 |
| EA202192320A1 (ru) | 2021-11-16 |
| MA55019A (fr) | 2021-12-29 |
| US12269813B2 (en) | 2025-04-08 |
| KR20210131371A (ko) | 2021-11-02 |
| BR112021016400A2 (pt) | 2021-10-13 |
| EP3927696C0 (en) | 2023-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285675A (en) | Crystalline form of 1-(1-oxo-2,1-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate | |
| IL287030A (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide as raf inhibitors for cancer therapy | |
| IL289875A (en) | 3. Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl- 1h-pyrazole-4-carboxamide | |
| MY205650A (en) | Crystalline forms | |
| NZ719975A (en) | Active compound combinations comprising a (thio)carboxamide derivative and a fungicidal compound | |
| PL3464276T3 (pl) | Nowa postać krystaliczna n-[5-(3,5-difluoro-benzylo)-1h-indazol-3-ilo)-4-(4-metylopiperazyn-1-ylo)-2-tetrahydropiran-4-yloamino)-benzamidu | |
| HUE064734T2 (hu) | 1-((2-(2,2,2-trifluoretoxi)piridin-4-il)metil)karbamid származékok mint KCNQ potenciátorok | |
| EP3433233A4 (en) | NOVEL CRYSTALLINE FORM OF 1- (5- (2,4-DIFLUORPHENYL) -1 - ((3- (FLUORPHENYL) SULFONYL) -4-METHOXY-1H-PYRROL-3-YL) -N-METHYLMETHANAMINE SALT | |
| IL271764A (en) | Crystalline form of N-[1-(5-cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide | |
| IL289881A (en) | Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h- tetrazole-5-carboxamide | |
| IL255224B (en) | Crystalline forms of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate | |
| CR20200216A (es) | Polimorfos y formas sòlidas de un compuesto de pirimidinilamino-pirazol y mèdtodos de producciòn | |
| IL272992A (en) | Solid structures of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide | |
| IL254943B (en) | -(4-(4-(((3r,5r)-5-((1h-4,2,1-triazol-1-yl)methyl)-5-(4,2-difluorophenyl)tetrahydrofuran-3-yl (Methoxy)-3-methylphenyl)piperazin-1-yl)-n-(2-hydroxycyclohexyl)benzamide antifungal or a pharmaceutically acceptable salt thereof | |
| HK40065506A (en) | Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate | |
| IL288158A (en) | Crystalline salt forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | |
| IL288577A (en) | Formulations of (s)-3-amino-6-methoxy-n-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide | |
| MX2017016042A (es) | Polimorfos de un compuesto de triazol que inhibe la pges-1. | |
| PH12018500898A1 (en) | Inhibitor of the p2x7 receptor | |
| HK40025427A (en) | Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide | |
| HK40075684B (en) | Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide | |
| MX2020002083A (es) | Composicion farmaceutica que comprende un inhibidor tirosina cinasa selectivo para receptores del factor de crecimiento de fibroblastos (fgfr). |